JP5792057B2 - 創傷治癒における瘢痕形成を低減するための組成物および方法 - Google Patents
創傷治癒における瘢痕形成を低減するための組成物および方法 Download PDFInfo
- Publication number
- JP5792057B2 JP5792057B2 JP2011502881A JP2011502881A JP5792057B2 JP 5792057 B2 JP5792057 B2 JP 5792057B2 JP 2011502881 A JP2011502881 A JP 2011502881A JP 2011502881 A JP2011502881 A JP 2011502881A JP 5792057 B2 JP5792057 B2 JP 5792057B2
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- annexin
- administered
- reducing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims description 17
- 230000029663 wound healing Effects 0.000 title claims description 16
- 238000000034 method Methods 0.000 title claims description 13
- 230000036573 scar formation Effects 0.000 title description 15
- 150000001875 compounds Chemical class 0.000 claims description 64
- 102000004121 Annexin A5 Human genes 0.000 claims description 26
- 108090000672 Annexin A5 Proteins 0.000 claims description 26
- 102000000412 Annexin Human genes 0.000 claims description 25
- 108050008874 Annexin Proteins 0.000 claims description 25
- 239000008194 pharmaceutical composition Substances 0.000 claims description 20
- 206010016654 Fibrosis Diseases 0.000 claims description 14
- 230000004761 fibrosis Effects 0.000 claims description 14
- 238000001802 infusion Methods 0.000 claims description 13
- 239000002105 nanoparticle Substances 0.000 claims description 12
- 239000011159 matrix material Substances 0.000 claims description 11
- 238000002316 cosmetic surgery Methods 0.000 claims description 10
- 238000001990 intravenous administration Methods 0.000 claims description 9
- 230000037390 scarring Effects 0.000 claims description 9
- 239000002537 cosmetic Substances 0.000 claims description 8
- 231100000241 scar Toxicity 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 239000006071 cream Substances 0.000 claims description 7
- 239000000499 gel Substances 0.000 claims description 7
- 210000002216 heart Anatomy 0.000 claims description 7
- 239000006210 lotion Substances 0.000 claims description 6
- 208000010125 myocardial infarction Diseases 0.000 claims description 6
- 206010019280 Heart failures Diseases 0.000 claims description 5
- 102000005741 Metalloproteases Human genes 0.000 claims description 5
- 108010006035 Metalloproteases Proteins 0.000 claims description 5
- 230000037396 body weight Effects 0.000 claims description 5
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 5
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 4
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 4
- 229960005475 antiinfective agent Drugs 0.000 claims description 4
- 239000004599 antimicrobial Substances 0.000 claims description 4
- 230000035876 healing Effects 0.000 claims description 4
- 239000003242 anti bacterial agent Substances 0.000 claims description 3
- 230000002424 anti-apoptotic effect Effects 0.000 claims description 3
- 229940088710 antibiotic agent Drugs 0.000 claims description 3
- 230000000747 cardiac effect Effects 0.000 claims description 3
- 239000002502 liposome Substances 0.000 claims description 3
- 150000003431 steroids Chemical class 0.000 claims description 3
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 2
- 208000014674 injury Diseases 0.000 claims description 2
- 230000008733 trauma Effects 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims 3
- 238000013152 interventional procedure Methods 0.000 claims 1
- 239000002831 pharmacologic agent Substances 0.000 claims 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 47
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 47
- 210000002950 fibroblast Anatomy 0.000 description 21
- 210000003491 skin Anatomy 0.000 description 13
- 210000002808 connective tissue Anatomy 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 6
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 6
- 206010052428 Wound Diseases 0.000 description 6
- 208000027418 Wounds and injury Diseases 0.000 description 6
- 210000002744 extracellular matrix Anatomy 0.000 description 6
- 239000003112 inhibitor Substances 0.000 description 6
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000000699 topical effect Effects 0.000 description 5
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 4
- 150000001413 amino acids Chemical group 0.000 description 4
- 230000008021 deposition Effects 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 210000002919 epithelial cell Anatomy 0.000 description 4
- 239000000835 fiber Substances 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 210000002510 keratinocyte Anatomy 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 230000003176 fibrotic effect Effects 0.000 description 3
- 230000008595 infiltration Effects 0.000 description 3
- 238000001764 infiltration Methods 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 238000013508 migration Methods 0.000 description 3
- 230000005012 migration Effects 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 238000011200 topical administration Methods 0.000 description 3
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 2
- 208000032544 Cicatrix Diseases 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 2
- 102100031358 Urokinase-type plasminogen activator Human genes 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 210000002469 basement membrane Anatomy 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 238000004040 coloring Methods 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 230000001744 histochemical effect Effects 0.000 description 2
- NITYDPDXAAFEIT-DYVFJYSZSA-N ilomastat Chemical compound C1=CC=C2C(C[C@@H](C(=O)NC)NC(=O)[C@H](CC(C)C)CC(=O)NO)=CNC2=C1 NITYDPDXAAFEIT-DYVFJYSZSA-N 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 210000000651 myofibroblast Anatomy 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000037309 reepithelialization Effects 0.000 description 2
- 230000037387 scars Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- -1 steroids Chemical class 0.000 description 2
- 238000007910 systemic administration Methods 0.000 description 2
- 230000009772 tissue formation Effects 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- FFTVPQUHLQBXQZ-KVUCHLLUSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O FFTVPQUHLQBXQZ-KVUCHLLUSA-N 0.000 description 1
- NTLKAXQBFYZMAH-UHFFFAOYSA-N 2-methylpentanamide Chemical class CCCC(C)C(N)=O NTLKAXQBFYZMAH-UHFFFAOYSA-N 0.000 description 1
- 108090000669 Annexin A4 Proteins 0.000 description 1
- 102000004148 Annexin A4 Human genes 0.000 description 1
- 108050002216 Annexin A8 Proteins 0.000 description 1
- 201000002829 CREST Syndrome Diseases 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- 102000005600 Cathepsins Human genes 0.000 description 1
- 108010084457 Cathepsins Proteins 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 208000006926 Discoid Lupus Erythematosus Diseases 0.000 description 1
- 208000013875 Heart injury Diseases 0.000 description 1
- 208000002260 Keloid Diseases 0.000 description 1
- 206010023330 Keloid scar Diseases 0.000 description 1
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 1
- 102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 description 1
- 102100026262 Metalloproteinase inhibitor 2 Human genes 0.000 description 1
- 102100026261 Metalloproteinase inhibitor 3 Human genes 0.000 description 1
- 102100024289 Metalloproteinase inhibitor 4 Human genes 0.000 description 1
- 108050006579 Metalloproteinase inhibitor 4 Proteins 0.000 description 1
- 208000003250 Mixed connective tissue disease Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010031023 Oral submucosal fibrosis Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 208000004362 Penile Induration Diseases 0.000 description 1
- 208000020758 Peyronie disease Diseases 0.000 description 1
- 241000097929 Porphyria Species 0.000 description 1
- 208000010642 Porphyrias Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000002847 Surgical Wound Diseases 0.000 description 1
- 201000009594 Systemic Scleroderma Diseases 0.000 description 1
- 206010042953 Systemic sclerosis Diseases 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 108010031374 Tissue Inhibitor of Metalloproteinase-1 Proteins 0.000 description 1
- 108010031372 Tissue Inhibitor of Metalloproteinase-2 Proteins 0.000 description 1
- 108010031429 Tissue Inhibitor of Metalloproteinase-3 Proteins 0.000 description 1
- 208000026911 Tuberous sclerosis complex Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- XFILPEOLDIKJHX-QYZOEREBSA-N batimastat Chemical compound C([C@@H](C(=O)NC)NC(=O)[C@H](CC(C)C)[C@H](CSC=1SC=CC=1)C(=O)NO)C1=CC=CC=C1 XFILPEOLDIKJHX-QYZOEREBSA-N 0.000 description 1
- 229950001858 batimastat Drugs 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 108010079785 calpain inhibitors Proteins 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000009787 cardiac fibrosis Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 208000017760 chronic graft versus host disease Diseases 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 229960002227 clindamycin Drugs 0.000 description 1
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 208000004921 cutaneous lupus erythematosus Diseases 0.000 description 1
- 201000001981 dermatomyositis Diseases 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 230000002327 eosinophilic effect Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000002390 hyperplastic effect Effects 0.000 description 1
- 229960003696 ilomastat Drugs 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 210000001117 keloid Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 201000010260 leiomyoma Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- OCSMOTCMPXTDND-OUAUKWLOSA-N marimastat Chemical compound CNC(=O)[C@H](C(C)(C)C)NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO OCSMOTCMPXTDND-OUAUKWLOSA-N 0.000 description 1
- 229950008959 marimastat Drugs 0.000 description 1
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 229960004023 minocycline Drugs 0.000 description 1
- 208000005207 oral submucous fibrosis Diseases 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000001095 phosphatidyl group Chemical group 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 239000002806 plasmin inhibitor Substances 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 201000002793 renal fibrosis Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000003998 snake venom Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229960002673 sulfacetamide Drugs 0.000 description 1
- SKIVFJLNDNKQPD-UHFFFAOYSA-N sulfacetamide Chemical compound CC(=O)NS(=O)(=O)C1=CC=C(N)C=C1 SKIVFJLNDNKQPD-UHFFFAOYSA-N 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 208000009999 tuberous sclerosis Diseases 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Description
静脈内投与を含む全身投与は、連続的投与(点滴)を使用して、あるいは反復もしくは1回の(ボーラス)注入により行うことができる。
この実験は、外科用メスでの切開により傷害を負った皮膚における線維芽細胞の浸潤および結合組織の沈着に対するアネキシンA5の効果を研究するためにデザインした。このデザインは、創傷治癒の一般的なモデルであり、たとえば心筋梗塞後の心臓で起こり得るため、創傷治癒の基本的プロセスを表す。
Nakao et al. United States Patent 5,360,789 (November 1, 1994)
Hiroshi Nakao, Masanao Watanabe and Masahiro MA: A new function of calphobindin I (annexin V) Promotion of both migration and urokinase-type plasminogen activator activity of normal human keratinocytes ; Eur. J. Biochem. (1994) vol. 223, pp 901-908.
Masanao Watanabe, Shoichi Kondo, Ken Mizuno, Wataru Yano, Hiroshi Nakao, Yukio Hattori, Kazuhiro Kimura, and Teruo Nishida; Promotion of Corneal Epithelial Wound Healing In Vitro and In Vivo by Annexin A5 Invest. Ophthalmol Vis Sci. 2006; 47:1862-1868.
[付記]以下に、出願当初の特許請求の範囲に記載された発明を付記する。
[項1] 創傷治癒における瘢痕を低減する際に使用するためのホスファチジルセリン結合化合物。
[項2] 前記ホスファチジルセリン結合化合物が全身に投与される、項1に記載のホスファチジルセリン結合化合物。
[項3] 前記ホスファチジルセリン結合化合物が、静脈内注入により投与される、項2に記載のホスファチジルセリン結合化合物。
[項4] 前記ホスファチジルセリン結合化合物が、クリーム、ゲルまたはローションにより局所的に投与される、項1に記載のホスファチジルセリン結合化合物。
[項5] 前記ホスファチジルセリン結合化合物が、アネキシンまたはその誘導体である、項1〜4の何れか1項に記載のホスファチジルセリン結合化合物。
[項6] 前記ホスファチジルセリン結合化合物が、アネキシンA5またはその誘導体である、項5に記載のホスファチジルセリン結合化合物。
[項7] 前記アネキシンまたはその誘導体が、分子のくぼんだ側に単一のシステイン残基を保持するアネキシンである、項5または6に記載のホスファチジルセリン結合化合物。
[項8] 前記ホスファチジルセリン結合化合物が、ナノ粒子に連結している、項7に記載のホスファチジルセリン結合化合物。
[項9] 前記ナノ粒子がリポソームである、項8に記載のホスファチジルセリン結合化合物。
[項10] 前記アネキシンが、直接またはナノ粒子を介して、抗感染剤、抗炎症剤、抗マトリクスメタロプロテイナーゼ剤、または抗アポトーシス剤に連結している、項7〜9の何れか1項に記載のホスファチジルセリン結合化合物。
[項11] 前記抗感染剤が、抗生物質のクラスに属する、項10に記載のホスファチジルセリン結合化合物。
[項12] 前記抗炎症剤が、ステロイドのクラスに属する、項10に記載のホスファチジルセリン結合化合物。
[項13] 前記抗マトリクスメタロプロテイナーゼ剤が、小さい化合物のクラスに属する、項10に記載のホスファチジルセリン結合化合物。
[項14] 前記ホスファチジルセリン結合化合物が、1日あたり0.002 mg/kg〜10 mg/kg体重患者の範囲内の1日量で投与される、項1〜13の何れか1項に記載のホスファチジルセリン結合化合物。
[項15] 前記創傷治癒が、心臓外傷の治癒である、項1に記載のホスファチジルセリン結合化合物。
[項16] 哺乳類被検体の心臓における線維形成を予防、抑制または低減する際に使用するためのホスファチジルセリン結合化合物。
[項17] 前記ホスファチジルセリン結合化合物が、静脈内注入により投与される、項16に記載のホスファチジルセリン結合化合物。
[項18] 前記ホスファチジルセリン結合化合物が、心膜内注入により投与される、項16に記載のホスファチジルセリン結合化合物。
[項19] 前記化合物が、心筋梗塞に罹患している哺乳類被検体に投与される、項16に記載のホスファチジルセリン結合化合物。
[項20] 前記化合物が、心不全の発症に対する可能性を低減するための治療の一部として哺乳類被検体に投与される、項18または19に記載のホスファチジルセリン結合化合物。
[項21] 心臓血管介入処置の一部として使用するための、項1〜18の何れか1項に記載のホスファチジルセリン結合化合物。
[項22] 効果的な量のホスファチジルセリン結合化合物を、それを必要とする人に投与することを含む、創傷治癒における瘢痕を低減するための美容的方法。
[項23] 形成外科手術の後治療(post-treatment)の一部としての、項22に記載の美容的方法。
[項24] 形成外科手術の一部として使用するための、項1〜18の何れか1項に記載のホスファチジルセリン結合化合物。
Claims (22)
- 有効成分として、アネキシンA5を含む、創傷治癒における瘢痕を低減するための薬学的組成物。
- 全身に投与される、請求項1に記載の薬学的組成物。
- 静脈内注入により投与される、請求項2に記載の薬学的組成物。
- クリーム、ゲルまたはローションにより局所的に投与される、請求項1に記載の薬学的組成物。
- 前記アネキシンが、分子のくぼんだ側に単一のシステイン残基を保持するアネキシンである、請求項1〜4の何れか1項に記載の薬学的組成物。
- 前記アネキシンが、ナノ粒子に連結している、請求項5に記載の薬学的組成物。
- 前記ナノ粒子がリポソームである、請求項6に記載の薬学的組成物。
- 前記アネキシンが、直接またはナノ粒子を介して、抗感染剤、抗炎症剤、抗マトリクスメタロプロテイナーゼ剤、または抗アポトーシス剤に連結している、請求項1〜4の何れか1項に記載の薬学的組成物。
- 前記抗感染剤が、抗生物質のクラスに属する、請求項8に記載の薬学的組成物。
- 前記抗炎症剤が、ステロイドのクラスに属する、請求項8に記載の薬学的組成物。
- 前記抗マトリクスメタロプロテイナーゼ剤が、150〜750Daの分子量を有する化合物のクラスに属する、請求項8に記載の薬学的組成物。
- 1日あたり0.002 mg/kg〜10 mg/kg体重の範囲内のアネキシンA5の1日量で投与される、請求項1〜11の何れか1項に記載の薬学的組成物。
- 前記創傷治癒が、心臓外傷の治癒である、請求項1に記載の薬学的組成物。
- 有効成分として、アネキシンA5を含む、哺乳類被検体の心臓の創傷治癒過程における線維形成を予防、抑制または低減するための薬学的組成物。
- 静脈内注入により投与される、請求項14に記載の薬学的組成物。
- 心膜内注入により投与される、請求項14に記載の薬学的組成物。
- 心筋梗塞に罹患している哺乳類被検体に投与される、請求項14に記載の薬学的組成物。
- 心不全の発症に対する可能性を低減するための治療の一部として哺乳類被検体に投与される、請求項16または17に記載の薬学的組成物。
- 前記瘢痕を低減することが、心臓血管介入処置の一部である、請求項1〜13の何れか1項に記載の薬学的組成物。
- 有効成分として、アネキシンA5を含む、創傷治癒における瘢痕を低減するための美容的組成物。
- 前記瘢痕を低減することが、形成外科手術の後治療(post-treatment)の一部である、請求項20に記載の美容的組成物。
- 前記瘢痕を低減することが、形成外科手術の一部である、請求項20に記載の美容的組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US4127808P | 2008-04-01 | 2008-04-01 | |
US61/041,278 | 2008-04-01 | ||
PCT/NL2009/050169 WO2009123454A1 (en) | 2008-04-01 | 2009-04-01 | Compositions and method for reducing scar formation in wound healing |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2011516469A JP2011516469A (ja) | 2011-05-26 |
JP5792057B2 true JP5792057B2 (ja) | 2015-10-07 |
Family
ID=40996620
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011502881A Active JP5792057B2 (ja) | 2008-04-01 | 2009-04-01 | 創傷治癒における瘢痕形成を低減するための組成物および方法 |
Country Status (8)
Country | Link |
---|---|
US (1) | US8377881B2 (ja) |
EP (1) | EP2268299B1 (ja) |
JP (1) | JP5792057B2 (ja) |
AU (1) | AU2009232478B2 (ja) |
CA (1) | CA2720280C (ja) |
DK (1) | DK2268299T3 (ja) |
ES (1) | ES2429122T3 (ja) |
WO (1) | WO2009123454A1 (ja) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11246913B2 (en) | 2005-02-03 | 2022-02-15 | Intarcia Therapeutics, Inc. | Suspension formulation comprising an insulinotropic peptide |
PL2359808T3 (pl) | 2006-08-09 | 2013-10-31 | Intarcia Therapeutics Inc | Osmotyczne systemy dostawcze i zespoły tłokowe |
MX2009011123A (es) | 2007-04-23 | 2009-11-02 | Intarcia Therapeutics Inc | Formulaciones de suspensiones de peptidos insulinotropicos y sus usos. |
EP2240155B1 (en) | 2008-02-13 | 2012-06-06 | Intarcia Therapeutics, Inc | Devices, formulations, and methods for delivery of multiple beneficial agents |
US20100178259A1 (en) * | 2009-01-12 | 2010-07-15 | The Regents Of The University Of Michigan | Reducing fibrosis using matrix metalloproteinase inhibitors |
NZ598686A (en) | 2009-09-28 | 2014-05-30 | Intarcia Therapeutics Inc | Rapid establishment and/or termination of substantial steady-state drug delivery |
US20120208755A1 (en) | 2011-02-16 | 2012-08-16 | Intarcia Therapeutics, Inc. | Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers |
US9889085B1 (en) | 2014-09-30 | 2018-02-13 | Intarcia Therapeutics, Inc. | Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c |
AU2016270984B2 (en) | 2015-06-03 | 2021-02-25 | Intarcia Therapeutics, Inc. | Implant placement and removal systems |
CN109310743A (zh) | 2016-05-16 | 2019-02-05 | 因塔西亚制药公司 | 胰高血糖素受体选择性多肽及其使用方法 |
USD840030S1 (en) | 2016-06-02 | 2019-02-05 | Intarcia Therapeutics, Inc. | Implant placement guide |
USD860451S1 (en) | 2016-06-02 | 2019-09-17 | Intarcia Therapeutics, Inc. | Implant removal tool |
EP3565580B1 (en) | 2017-01-03 | 2024-03-06 | i2o Therapeutics, Inc. | Continuous administration of exenatide and co-adminstration of acetaminophen, ethinylestradiol or levonorgestrel |
USD933219S1 (en) | 2018-07-13 | 2021-10-12 | Intarcia Therapeutics, Inc. | Implant removal tool and assembly |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0558751B1 (en) | 1990-11-20 | 2000-02-02 | Kowa Co. Ltd. | Therapeutic agent for the treatment of wounds |
US6333347B1 (en) | 1999-01-29 | 2001-12-25 | Angiotech Pharmaceuticals & Advanced Research Tech | Intrapericardial delivery of anti-microtubule agents |
US7511016B2 (en) * | 2004-07-07 | 2009-03-31 | Mosamedix B.V. | Annexins, derivatives thereof, and annexin-cys variants, as well as therapeutic and diagnostic uses thereof |
US8067357B2 (en) * | 2005-12-12 | 2011-11-29 | Mosamedix B.V. | Annexin derivatives suitable for pretargeting in therapy and diagnosis |
-
2009
- 2009-04-01 AU AU2009232478A patent/AU2009232478B2/en not_active Ceased
- 2009-04-01 US US12/935,900 patent/US8377881B2/en active Active
- 2009-04-01 WO PCT/NL2009/050169 patent/WO2009123454A1/en active Application Filing
- 2009-04-01 ES ES09728723T patent/ES2429122T3/es active Active
- 2009-04-01 CA CA2720280A patent/CA2720280C/en active Active
- 2009-04-01 JP JP2011502881A patent/JP5792057B2/ja active Active
- 2009-04-01 DK DK09728723.9T patent/DK2268299T3/da active
- 2009-04-01 EP EP09728723.9A patent/EP2268299B1/en active Active
Also Published As
Publication number | Publication date |
---|---|
ES2429122T3 (es) | 2013-11-13 |
AU2009232478B2 (en) | 2014-11-06 |
WO2009123454A1 (en) | 2009-10-08 |
US20110091527A1 (en) | 2011-04-21 |
CA2720280A1 (en) | 2009-10-08 |
US8377881B2 (en) | 2013-02-19 |
CA2720280C (en) | 2018-02-20 |
EP2268299A1 (en) | 2011-01-05 |
DK2268299T3 (da) | 2013-10-07 |
JP2011516469A (ja) | 2011-05-26 |
AU2009232478A1 (en) | 2009-10-08 |
EP2268299B1 (en) | 2013-07-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5792057B2 (ja) | 創傷治癒における瘢痕形成を低減するための組成物および方法 | |
KR20080031405A (ko) | 상피 재생의 촉진 | |
BR112012001491B1 (pt) | Preparação terapêutica para tratar dermatite e uso de uma preparação terapêutica | |
EP2544706B1 (en) | Modulating aquaporins with relaxin | |
MXPA02011622A (es) | Utilizacion de derivados de biguanida para fabricar un medicamento que tiene un efecto cicatrizante. | |
US9023792B2 (en) | Method for treating keloid and hypertrophic scars by administration of bFGF | |
US20060293228A1 (en) | Therapeutic compositions and methods using transforming growth factor-beta mimics | |
WO2013059879A1 (en) | Compositions and methods for the treatment of fibrosis and fibrotic diseases | |
EA010650B1 (ru) | Защищающие ткань цитокины для лечения и профилактики сепсиса и образования спаек | |
WO2002085117A1 (en) | Methods and compositions for preventing and treating septic shock and endotoxemia | |
US20200297649A1 (en) | Devices and methods for delivery of oxygen to a wound | |
CN106983738B (zh) | 甲状腺激素及其药学上可接受的盐或前药在制备治疗和/或预防皮肤疾病的药物中的应用 | |
PT1482967E (pt) | Composições farmacêuticas e cosmética compreendendo plgf-1 | |
JP5579523B2 (ja) | 創傷治療のための医薬 | |
AU2021394748A1 (en) | Compositions and methods for treating wounds | |
Ellger et al. | Normoglycemia and not glycemia-independent actions of insulin maintain physiologic NOS-activity by preserving physiological regulation of ADMA-levels: 12AP4-3 | |
JP2001514629A (ja) | 薬剤製造へのヒトα▲下1▼−酸性糖蛋白質の使用法 | |
JP2002538087A (ja) | 薬学的調製物を製造するためのオロソムコイドの使用 | |
JPH06179628A (ja) | 創傷治癒促進剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20120309 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130820 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20131120 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20131127 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140220 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20141021 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150121 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20150707 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150805 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5792057 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |